Search News Year All202620252024202320222021 05/29/2025 Zevra Announces Final Results of 2025 Annual Meeting of Stockholders Read More 05/21/2025 All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees Read More 05/13/2025 Zevra Reports First Quarter 2025 Financial Results and Corporate Update Read More 05/06/2025 Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call Read More 05/01/2025 Zevra Therapeutics to Participate in the Citizens Life Science Conference Read More 04/21/2025 Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders Read More 04/17/2025 Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism Read More 04/07/2025 Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million Read More 03/31/2025 Zevra Therapeutics Files Preliminary Proxy Read More 03/11/2025 Zevra Reports Full Year 2024 and Fourth Quarter Financial Results Read More
05/21/2025 All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees Read More
04/17/2025 Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism Read More
04/07/2025 Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million Read More
News
Careers
Contacts